Research programme: macrocyclic peptide therapeutics - Circle PharmaAlternative Names: Cancer therapeutics - Circle Pharma
Latest Information Update: 15 Sep 2016
At a glance
- Originator Circle Pharma
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Intracellular signalling peptide and protein inhibitors; Protein-protein interaction inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer